BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25373854)

  • 1. Timing and characteristics of radiation pneumonitis after stereotactic body radiotherapy for peripherally located stage I lung cancer.
    Kanemoto A; Matsumoto Y; Sugita T
    Int J Clin Oncol; 2015 Aug; 20(4):680-5. PubMed ID: 25373854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of Radiation Pneumonitis After Stereotactic Body Radiotherapy: Effect of Pulmonary Emphysema Quantitated Using CT Images.
    Yamamoto T; Kadoya N; Sato Y; Matsushita H; Umezawa R; Kubozono M; Ishikawa Y; Kozumi M; Takahashi N; Morishita Y; Katagiri Y; Sato K; Ito K; Takeda K; Jingu K
    Clin Lung Cancer; 2018 Jan; 19(1):e85-e90. PubMed ID: 28655592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes and Predictors of Lung Toxicity After Multiple Courses of Lung Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
    Muller DA; Dutta SW; Aliotta E; Sanders JC; Wijesooriya K; Watkins WT; Larner JM
    Clin Lung Cancer; 2021 May; 22(3):234-241. PubMed ID: 32690439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic analysis of radiation pneumonitis: carbon-ion radiotherapy in patients with locally advanced lung cancer.
    Hayashi K; Yamamoto N; Karube M; Nakajima M; Matsufuji N; Tsuji H; Ogawa K; Kamada T
    Radiat Oncol; 2017 May; 12(1):91. PubMed ID: 28558766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetric factors predicting radiation pneumonitis after CyberKnife stereotactic body radiotherapy for peripheral lung cancer.
    Nakamura M; Nishimura H; Nakayama M; Mayahara H; Uezono H; Harada A; Hashimoto N; Ejima Y; Ishihara T; Sasaki R
    Br J Radiol; 2016 Dec; 89(1068):20160560. PubMed ID: 27805837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early graphical appearance of radiation pneumonitis correlates with the severity of radiation pneumonitis after stereotactic body radiotherapy (SBRT) in patients with lung tumors.
    Takeda A; Ohashi T; Kunieda E; Enomoto T; Sanuki N; Takeda T; Shigematsu N
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):685-90. PubMed ID: 20510193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy.
    Barriger RB; Forquer JA; Brabham JG; Andolino DL; Shapiro RH; Henderson MA; Johnstone PA; Fakiris AJ
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):457-62. PubMed ID: 21035956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy.
    Takeda A; Kunieda E; Ohashi T; Aoki Y; Oku Y; Enomoto T; Nomura K; Sugiura M
    Chest; 2012 Apr; 141(4):858-866. PubMed ID: 21885726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting risk factors for radiation pneumonitis after stereotactic body radiation therapy for primary or metastatic lung tumours.
    Okubo M; Itonaga T; Saito T; Shiraishi S; Mikami R; Nakayama H; Sakurada A; Sugahara S; Koizumi K; Tokuuye K
    Br J Radiol; 2017 May; 90(1073):20160508. PubMed ID: 28195507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy.
    Liu H; Zhang X; Vinogradskiy YY; Swisher SG; Komaki R; Chang JY
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):1017-23. PubMed ID: 22543216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeat stereotactic body radiotherapy (SBRT) for local recurrence of non-small cell lung cancer and lung metastasis after first SBRT.
    Ogawa Y; Shibamoto Y; Hashizume C; Kondo T; Iwata H; Tomita N; Ogino H
    Radiat Oncol; 2018 Jul; 13(1):136. PubMed ID: 30055636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer.
    Matsuo Y; Shibuya K; Nakamura M; Narabayashi M; Sakanaka K; Ueki N; Miyagi K; Norihisa Y; Mizowaki T; Nagata Y; Hiraoka M
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e545-9. PubMed ID: 22436782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Pneumonitis After Stereotactic Body Radiation Therapy in Patients With Previous Anatomic Lung Resection.
    Hayes JT; David EA; Qi L; Chen AM; Daly ME
    Clin Lung Cancer; 2015 Sep; 16(5):379-84. PubMed ID: 25737143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of clinical, tumour-related and dosimetric factors in grade 0-1, grade 2 and grade 3 radiation pneumonitis after stereotactic body radiotherapy for lung tumours.
    Takeda A; Ohashi T; Kunieda E; Sanuki N; Enomoto T; Takeda T; Oku Y; Shigematsu N
    Br J Radiol; 2012 May; 85(1013):636-42. PubMed ID: 22253343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study.
    Watanabe K; Katsui K; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
    Radiat Oncol; 2021 Feb; 16(1):39. PubMed ID: 33622369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer.
    Ueki N; Matsuo Y; Togashi Y; Kubo T; Shibuya K; Iizuka Y; Mizowaki T; Togashi K; Mishima M; Hiraoka M
    J Thorac Oncol; 2015 Jan; 10(1):116-25. PubMed ID: 25376512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk and predictors for severe radiation pneumonitis in lung cancer patients treated with thoracic reirradiation.
    Ren C; Ji T; Liu T; Dang J; Li G
    Radiat Oncol; 2018 Apr; 13(1):69. PubMed ID: 29661254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary dose-volume predictors of radiation pneumonitis following stereotactic body radiation therapy.
    Harder EM; Park HS; Chen ZJ; Decker RH
    Pract Radiat Oncol; 2016; 6(6):e353-e359. PubMed ID: 27156424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.
    Feddock J; Arnold SM; Shelton BJ; Sinha P; Conrad G; Chen L; Rinehart J; McGarry RC
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1325-31. PubMed ID: 23265574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis.
    Yamaguchi S; Ohguri T; Ide S; Aoki T; Imada H; Yahara K; Narisada H; Korogi Y
    Lung Cancer; 2013 Nov; 82(2):260-5. PubMed ID: 24054547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.